Results: 31
Benzimidazole‐carbamate anthelmintics: Perspective candidates for the anticancer drug development.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 296, doi. 10.1002/ddr.21933
- By:
- Publication type:
- Article
CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR‐506‐3p/NFIB axis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 512, doi. 10.1002/ddr.21882
- By:
- Publication type:
- Article
Recent research brings hope for reshaping the co‐evolutionary arms race against parasitic infectious diseases.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 219, doi. 10.1002/ddr.21922
- By:
- Publication type:
- Article
Novel strategies to oral delivery of insulin: Current progress of nanocarriers for diabetes management.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 301, doi. 10.1002/ddr.21903
- By:
- Publication type:
- Article
Troxerutin regulates HIF‐1α by activating JAK2/STAT3 signaling to inhibit oxidative stress, inflammation, and apoptosis of cardiomyocytes induced by H<sub>2</sub>O<sub>2</sub>.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 552, doi. 10.1002/ddr.21885
- By:
- Publication type:
- Article
IL2‐inducible T‐cell kinase inhibitor ibrutinib reduces symptoms and Th2 differentiation in mouse allergic‐rhinitis model.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 544, doi. 10.1002/ddr.21884
- By:
- Publication type:
- Article
Exploration of novel TOSMIC tethered imidazo[1,2‐a]pyridine compounds for the development of potential antifungal drug candidate.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 525, doi. 10.1002/ddr.21883
- By:
- Publication type:
- Article
Road‐map of pre‐clinical treatment for Visceral Leishmaniasis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 317, doi. 10.1002/ddr.21907
- By:
- Publication type:
- Article
Fraxetin exerts anticancer effect in glioma by suppressing MiR‐21‐3p.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 501, doi. 10.1002/ddr.21881
- By:
- Publication type:
- Article
Design, synthesis, biological evaluation, and molecular docking of new benzofuran and indole derivatives as tubulin polymerization inhibitors.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 485, doi. 10.1002/ddr.21880
- By:
- Publication type:
- Article
New chromanone derivatives containing thiazoles: Synthesis and antitumor activity evaluation on A549 lung cancer cell line.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 470, doi. 10.1002/ddr.21879
- By:
- Publication type:
- Article
Astragaloside IV enhances the sensibility of lung adenocarcinoma cells to bevacizumab by inhibiting autophagy.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 461, doi. 10.1002/ddr.21878
- By:
- Publication type:
- Article
Retraction.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 564, doi. 10.1002/ddr.21876
- Publication type:
- Article
Design and testing of selective inactivators against an antifungal enzyme target.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 447, doi. 10.1002/ddr.21875
- By:
- Publication type:
- Article
Paeonol inhibits human lung cancer cell viability and metastasis in vitro via miR‐126‐5p/ZEB2 axis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 432, doi. 10.1002/ddr.21873
- By:
- Publication type:
- Article
Receptor interacting protein kinase 4 promotes cell proliferation, migration, and invasion in ovarian cancer via targeting protein kinase C delta.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 407, doi. 10.1002/ddr.21871
- By:
- Publication type:
- Article
Conventional and microwave‐assisted organic synthesis of novel antimycobacterial agents bearing furan and pyridine hybrids.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 416, doi. 10.1002/ddr.21872
- By:
- Publication type:
- Article
Propofol promotes migration, alleviates inflammation, and apoptosis of lipopolysaccharide‐induced human pulmonary microvascular endothelial cells by activating PI3K/AKT signaling pathway via upregulating APOM expression.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 397, doi. 10.1002/ddr.21869
- By:
- Publication type:
- Article
Naringenin inhibits autophagy and epithelial‐mesenchymal transition of human lens epithelial cells by regulating the Smad2/3 pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 389, doi. 10.1002/ddr.21868
- By:
- Publication type:
- Article
Apatinib weakens resistance of gastric cancer cells to paclitaxel by suppressing JAK/STAT3 signaling pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 379, doi. 10.1002/ddr.21867
- By:
- Publication type:
- Article
Effective and transient mapping of protein–protein interactions: Application of novel releasable photoaffinity linkers.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 368, doi. 10.1002/ddr.21866
- By:
- Publication type:
- Article
Ketotifen is a Prodrug. Norketotifen is the active metabolite.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 362, doi. 10.1002/ddr.21865
- By:
- Publication type:
- Article
MicroRNA‐214‐5p aggravates sepsis‐related acute kidney injury in mice.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 339, doi. 10.1002/ddr.21863
- By:
- Publication type:
- Article
CircTHBS1 facilitates the progression of interstitial cystitis depending on the regulation of miR‐139‐5p/MFN2 axis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 351, doi. 10.1002/ddr.21864
- By:
- Publication type:
- Article
RNA editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non‐small cell lung cancer cells to anlotinib by regulating CX3CR1‐fractalkine expression.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 328, doi. 10.1002/ddr.21861
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 217, doi. 10.1002/ddr.21824
- Publication type:
- Article
Repurposing topical triclosan for cutaneous leishmaniasis: Preclinical efficacy in a murine Leishmania (L.) amazonensis model.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 285, doi. 10.1002/ddr.21725
- By:
- Publication type:
- Article
The current drug discovery landscape for trypanosomiasis and leishmaniasis: Challenges and strategies to identify drug targets.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 225, doi. 10.1002/ddr.21664
- By:
- Publication type:
- Article
A simple, robust, and affordable bioluminescent assay for drug discovery against infective African trypanosomes.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 253, doi. 10.1002/ddr.21634
- By:
- Publication type:
- Article
QSAR studies on benzothiophene derivatives as Plasmodium falciparum N‐myristoyltransferase inhibitors: Molecular insights into affinity and selectivity.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 264, doi. 10.1002/ddr.21646
- By:
- Publication type:
- Article
Impelling TLR9: Road to perspective vaccine for visceral leishmaniasis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 2, p. 222, doi. 10.1002/ddr.21662
- By:
- Publication type:
- Article